SCHEDULE: Farallon Amends Tango Therapeutics Stake, Updates Key Personnel
Beneficial Ownership Report
Farallon Capital Management and its affiliates filed an amended Schedule 13G for Tango Therapeutics, Inc., disclosing beneficial ownership of 9.99% of common stock and changes in its internal managing members.
Summary
- Farallon Capital Management and its affiliated entities (the "Reporting Persons") collectively reported beneficial ownership of 13,461,215 shares of Tango Therapeutics, Inc. common stock.
- This represents 9.99% of Tango Therapeutics' outstanding common stock.
- The total beneficial ownership includes 13,391,411 direct shares and 69,804 shares exercisable from Pre-Funded Common Stock Purchase Warrants within 60 days.
- An additional 2,089,988 Warrants are held but not considered beneficially owned due to a 9.99% ownership limitation.
- The filing is an Amendment No. 3 to a Schedule 13G, indicating an update to previous disclosures.
- The filing also details changes in the managing members of the Farallon entities, affecting who is deemed a beneficial owner.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, factual disclosure of beneficial ownership and internal management changes within the reporting entity, Farallon Capital, with no direct positive or negative implications for Tango Therapeutics' operational performance.
Positives
- Farallon Capital Management maintains a significant stake in Tango Therapeutics, indicating continued investment interest.
Risks
- The beneficial ownership limitation on warrants means a substantial portion of held warrants (2,089,988 shares) cannot be exercised if it would push beneficial ownership above 9.99%, potentially limiting future upside from these instruments for Farallon.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors holding significant stakes, providing transparency into major shareholder positions. Farallon Capital's continued 9.99% stake in Tango Therapeutics, a biotechnology company, suggests ongoing confidence in the sector or the company's pipeline, aligning with broader trends of institutional investment in innovative healthcare firms.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Managing Member/Manager of Farallon entities | NA | Avner A. Husen | 01/01/2026 | Became a member/manager, leading to deemed beneficial ownership of Tango Therapeutics shares held by Farallon Funds. |
| Managing Member/Manager of Farallon entities | Richard B. Fried | NA | 12/31/2025 | Ceased to be a member/manager, no longer deemed a beneficial owner of Tango Therapeutics shares held by Farallon Funds. |
| Managing Member/Manager of Farallon entities | Rajiv A. Patel | NA | 12/31/2025 | Ceased to be a member/manager, no longer deemed a beneficial owner of Tango Therapeutics shares held by Farallon Funds. |
| Managing Member/Manager of Farallon entities | William Seybold | NA | 12/31/2025 | Ceased to be a member/manager, no longer deemed a beneficial owner of Tango Therapeutics shares held by Farallon Funds. |
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Date of event requiring the filing of this statement, and effective date for cessation of certain Farallon managing members. |
| 01/01/2026 | Effective date for Avner A. Husen becoming a managing member of Farallon entities. |
| 02/06/2026 | Date of signing for the Schedule 13G Amendment No. 3. |
Keywords
Tango Therapeutics, Farallon Capital, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Institutional Investor, Biotechnology, Healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.